This study aims to provide real-world information about the duration, safety, and overall benefit of DaxibotulinumtoxinA (also called DAXI) treatment for adults living with blepharospasm (BSP), a condition that causes uncontrolled blinking or muscle spasms around the eyes, which can interfere with vision and daily activities. Specifically, it is being done to learn more about how well and how long DAXI works for treating adults with blepharospasm.
This is a single-center, open-label, single-arm study, meaning everyone in the study will receive DAXI, and both participants and researchers will know what treatment is being given. The study will include 20 adult participants.
Participants may receive two to three treatment cycles of DAXI injections over about 12 months. The timing between treatments will depend on how long each injection works for each person. Injections will be given at least every 90 days (3 months) but no later than every 180 days (6 months). Participants and their doctors will decide when another injection is needed based on symptom control using a tool called the Blepharospasm Severity Tracker Form (BSTF). To make the injections more comfortable, participants may use topical lidocaine cream, cooling spray, or another local anesthetic before injection.
DAXI will be prepared by the injecting clinician or trained staff right before use. The medication is made by mixing a measured amount of DAXI powder with a small amount of sterile saline solution (salt water) to reach the correct concentration. The exact injection technique (including the dose, location, and number of injection sites) will be chosen by the injector based on each participant's needs, but treatment will only be given in specific facial muscles (corrugator, procerus, orbicularis oculi, and nasalis). The use of imaging tools such as electromyography (EMG) or ultrasound is optional and typically not required for injections around the eyes.
The starting DAXI dose will be based on each participant's current or previous botulinum toxin treatment:
* If the participant was previously treated with onabotulinumtoxinA (Botox®), the same number of "units" will be used for DAXI (a 1:1 conversion).
* If the participant was previously treated with incobotulinumtoxinA (Xeomin®), the DAXI dose will be adjusted to about two-thirds of the previous incobotulinumtoxinA dose (a 1.5:1 conversion).
If a participant experienced side effects such as droopy eyelids (ptosis), double vision (diplopia), or dry eyes with prior treatments, that information will help guide dosing decisions. For later injection cycles, the injector may adjust the dose or injection pattern based on how well the participant responds. Whenever possible, the same injector will perform all of a participant's treatments to keep results consistent.
Participants will come to the clinic for in-person visits for most study assessments. After each DAXI injection, the peak effect (best response) will be evaluated about one month later, guided by the BSTF. These visits may be done remotely (via phone or video) when appropriate. The same schedule will be followed for future cycles. For the final treatment, this one-month check will occur unless the participant reports that the treatment's full effect happened sooner.
The main goal (primary endpoint) of the study is to measure how long DAXI's effects last, specifically by tracking the median time until the next injection is needed.
Other key goals (secondary endpoints) include:
* How long participants feel the treatment works
* How severe their blepharospasm symptoms are over time
* What side effects or safety concerns occur (adverse events)

开始日期2026-10-01

申办/合作机构

University of Pennsylvania

[+1]

NCT06195241

/ Recruiting临床4期IIT

The Safety and Efficacy of DaxibotulinumtoxinA-Lanm for Benign Essential Blepharospasm and Hemifacial Spasm

The goal of this clinical trial is to test the effects of DaxibotulinumtoxinA-Lanm (Daxxify) in patients with benign essential blepharospasms (BEB) and hemifacial spasms (HFS). The main questions to answer:
1. Is there clinically significant difference (measured by Jankovic Rating Scale (JRS) score from base to peak efficacy) for patients with BEB and HFS treated with Daxxify?
2. What percentage of patients achieve a clinical response?
Participants historically treated with Botox for either BEB or HFS will be crossed over to Daxxify treatment in order to serve as their own control and examine the efficacy of Daxxify.

开始日期2025-02-11

申办/合作机构

Montefiore Medical Center

[+1]

NCT06411002

/ Completed临床2期

A Phase 2a Study to Evaluate the Effects of DaxibotulinumtoxinA for Injection on the Treatment of Dynamic Forehead Lines and Glabellar Lines

This is a Phase 2a open-label, single-arm study to evaluate the effects of DaxibotulinumtoxinA-lanm (DAXI) for Injection on the treatment of dynamic forehead lines (FHL) and glabellar lines (GL).
Approximately 40 subjects (18 years of age and above) with moderate to severe GL and FHL (all assessed at maximum contraction) will be screened for eligibility with the goal of enrolling and treating 30 subjects to receive DAXI for injection after providing informed consent.
The primary objective of this study is to determine the efficacy and safety of the combined treatment of two upper facial regions with DAXI for injection.

开始日期2024-04-08

申办/合作机构

Revance Therapeutics, Inc.

100 项与 Daxibotulinumtoixn A-LANM 相关的临床结果

登录后查看更多信息

100 项与 Daxibotulinumtoixn A-LANM 相关的转化医学

登录后查看更多信息

100 项与 Daxibotulinumtoixn A-LANM 相关的专利（医药）

登录后查看更多信息

项与 Daxibotulinumtoixn A-LANM 相关的文献（医药）

2026-09-01·ANAEROBE

Molecular epidemiology of Clostridioides difficile clinical isolates in a tertiary-care hospital of northern Mexico: single-center real-life study

Article

作者: Camacho-Ortiz, Adrián ; Alcalá-Zúñiga, Daphne ; Domínguez-Rivera, Cristian V ; Bocanegra-Ibarias, Paola ; Salas-Treviño, Daniel ; Flores-Treviño, Samantha

OBJECTIVES:

Currently, Clostridioides difficile infections (CDIs) are one of the leading causes of nosocomial infections worldwide. In Latin America, the most economically developed countries have seen a rise in these infections in recent years, likely driven by expanded hospital capacity and shifting demographic patterns. However, epidemiological data on CDIs in Mexico are scarce. In this study, we evaluated the current molecular epidemiological situation in a tertiary-care hospital in northern Mexico and correlated it with clinical and laboratory data to identify indicators of infection with the hypervirulent RT027 ribotype.

METHODS:

This was a prospective, cross-sectional, analytical, and observational study. Samples were collected from patients with confirmed CDIs using a two-step algorithm. Cultures and molecular analyses were performed for toxigenic classification and ribotyping of the C. difficile strains. Clinical data were also collected to perform correlation analyses with the ribotypes.

RESULTS:

In this study, 71 C difficile strains were collected from 111 samples available for analysis. The genes for toxins A and B were found in 85.9% (61/71) and 81.7% (58/71) of the samples, respectively, while the gene for the binary toxin was detected in 52.1% (37/71) of the samples. RT027 was the most frequently isolated strain (50.7%, 36/71), followed by RT001 (11.3%, 8/71). None of the RTs analyzed showed significant changes over the years of analysis; however, the presence of RT002 and RT014 appeared more frequently in the later years. Patient age was slightly increased in RT027 CDIs, without reaching significance (p = 0.071); days of hospitalization, previous hospitalizations, antibiotic use, ATLAS and Charlson score values showed no differences between RT027 and other ribotypes CDIs.

CONCLUSIONS:

In our study, we observed a moderate predominance of RT027 over the past four years, and the presence of various RTs associated with community-acquired CDIs. Patient age was slightly increased in patients who presented with CDI caused by RT027; however, this data was not statistically significant. More comprehensive studies with larger sample sizes and longer analysis periods are needed to determine the epidemiological shifts in C. difficile ribotypes in Mexico.

2026-07-01·Movement Disorders Clinical Practice

Article

作者: Lee, Han S. ; Sparrow, Julia ; Ellenbogen, Aaron ; Patel, Atul T. ; Bahroo, Laxman ; Kazerooni, Rashid ; McAllister, Peter ; Gross, Todd M. ; Gallagher, Conor J. ; Hauser, Robert A. ; Hollander, David A.

ABSTRACT:

Background:

DaxibotulinumtoxinA for injection (DAXI), a novel botulinum toxin (BoNT) formulated with a custom‐engineered peptide, was recently approved for treating cervical dystonia (CD). DAXI demonstrated a long duration of symptom relief in Phase 3 trials.

Objective:

To report findings from PrevU, an early experience, real‐world observational program initiated following DAXI's FDA approval.

Methods:

Movement disorder specialists were provided with DAXI to treat CD patients per routine clinical practice, and were surveyed on dosing patterns and treatment intervals across the first three cycles of DAXI as doses were optimized.

Results:

A total of 234 CD patients (206 receiving BoNT treatment and 28 BoNT‐naïve) received a total of 589 DAXI treatments. Among patients with prior BoNT therapy, breakthrough symptoms within 12 weeks of prior BoNT therapy was the most common reason for patient selection (76.2%), and onabotulinumtoxinA was the most common prior toxin (68.4%). DAXI dose was titrated from a mean of 244.4 U (median 250 U) to 314.7 U (median 300 U) by Cycle 3. The ratio of DAXI dose to normalized prior BoNT dose was approximately 1.1:1 at initiation and 1.4:1 at Cycle 3. The mean (SD) time to re‐treatment across all DAXI cycles was 16.1 (5.6) weeks for all patients and 15.7 (4.5) weeks for patients with a history of breakthrough before 12 weeks with prior toxin. The most common adverse events were muscle weakness (2.4% of treatments), injection pain (1.4% of treatments), and dysphagia (0.3% of treatments).

Conclusions:

In this real‐world setting, DAXI demonstrated extended clinical benefit and a favorable safety profile.

2026-06-01·AESTHETIC PLASTIC SURGERY

Challenging Interchangeability: Dynamic Dose-Response Modelling of Botulinum Toxin A Products

Article

作者: Webb, William Richard ; Wu, Woffles T L ; Rao, Parinitha ; Rahman, Eqram ; Sayed, Karim ; Avelar, Rui ; Carruthers, Jean D A

INTRODUCTION:

Botulinum Neurotoxin type A (BoNT-A) formulations are used worldwide for both aesthetic and therapeutic indications, yet dose conversion between products remains based on empirical ratios that ignore pharmacodynamic variability. This study aimed to generate dynamic, time-resolved dose equivalence estimates for six FDA-approved BoNT-A formulations, onabotulinumtoxinA (ONA), abobotulinumtoxinA (ABO), incobotulinumtoxinA (INCO), daxibotulinumtoxinA (DAXI), prabotulinumtoxinA (PRABO), and letibotulinumtoxinA (LETI) and to assess how their clinical performance differs over time.

METHODS:

A hybrid, time-resolved in silico pharmacodynamic model was developed to simulate onset, peak effect, and decay kinetics using data aggregated from 49 clinical trials and regulatory submissions. Each formulation was modelled in 10,000 virtual patients to capture real-world variability in EC₅₀, maximal efficacy, and decay rate. Dose equivalence relative to 20 U of ONA was determined using two independent metrics: the area under the response curve (AURC) and time above a standardized efficacy threshold. External validation was performed against independent clinical datasets.

RESULTS:

Simulated durations ranged from 10.6 weeks (ABO) to 14.5 weeks (PRABO), matching published clinical means within ±1.2 weeks. Time-resolved conversion ratios revealed significant temporal drift: ABO increased from 2.0 to 2.7 (≈35% drift), LETI from 1.1 to 1.4 (≈27 %), while DAXI and PRABO demonstrated decreasing ratios (≈15% drift), reflecting superior persistence. Efficiency analysis ranked PRABO and DAXI highest (AURC/unit = 0.059 and 0.057), followed by ONA (0.050), INCO (0.040), LETI (0.035), and ABO (0.031). Global sensitivity analysis identified decay rate (koff) as the dominant determinant of efficacy duration (Sobol index = 0.52).

CONCLUSION:

Static dose conversion ratios fail to represent the dynamic pharmacodynamic behaviour of BoNT-A formulations. This simulation-based, data-driven approach reproduces clinical outcomes with high fidelity and provides a robust framework for effect-based dose equivalence, improving precision in product substitution and individualized treatment planning.

LEVEL OF EVIDENCE IV:

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.

187

项与 Daxibotulinumtoixn A-LANM 相关的新闻（医药）

2026-09-01

·allsci.com

Revelyx launches with recombinant botulinum toxin ready for Phase II readout

Nashville-based Revelyx Bio has launched as a clinical-stage company built around an exclusive license from China-based Chongqing Claruvis Pharmaceutical for YY003, a recombinant botulinum toxin type A (rBoNT/A) in a ready-to-use liquid formulation. Revelyx holds rights to develop and commercialize YY003 for aesthetic and therapeutic indications globally, excluding mainland China, Hong Kong, and Macau. Financial terms were not disclosed. YY003 is produced via recombinant expression in E. coli rather than conventional Clostridium botulinum fermentation, a manufacturing distinction Claruvis describes as offering greater control over neurotoxin identity and purity. The ready-to-use prefilled syringe format eliminates the reconstitution step required for currently approved leading botulinum toxin products. The US FDA cleared an investigational new drug application for YY003 in September 2024, and a Phase II study in adults with moderate-to-severe glabellar lines has been completed. Revelyx said it expects to report topline data in Q3 2026. Claruvis's platform credentials are anchored by Retoxin (YY001), a related lyophilized rBoNT/A that received approval from China's National Medical Products Administration in March 2026 — the first approved recombinant botulinum toxin type A anywhere in the world. YY003 is a distinct asset, differentiated from Retoxin primarily by its liquid formulation. Claruvis is separately advancing Retoxin in a Phase III trial in China for upper-limb spasticity secondary to stroke. The deal is Revelyx's founding transaction. The company is backed by NRL Capital, whose founding partner Xianghong Lin also founded BioBay, a major life sciences park in Suzhou. Dustin Sjuts, appointed CEO at launch, most recently served as president of Revance Therapeutics, where he oversaw the FDA approvals and US commercial launches of daxibotulinumtoxinA-lanm (Daxxify) for glabellar lines and cervical dystonia. The structure — a purpose-built Western company formed around a single-asset exclusive license from an Asian originator, with the originator retaining Greater China rights — resembles the model used by Evolus, which was built around an exclusive license from South Korea's Daewoong Pharmaceutical for prabotulinumtoxinA (Jeuveau) covering the US and Europe. In the botulinum toxin market, approved competitors — including onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), prabotulinumtoxinA (Jeuveau), and letibotulinumtoxinA (Letybo) — are all derived from bacterial fermentation and require reconstitution before injection. No rBoNT/A has been approved by the FDA. Revelyx has stated its goal is to deliver the first FDA-approved recombinant botulinum neurotoxin type A. Spot something wrong? Report an issue with this article

2026-08-31

·BioSpace

Revelyx Bio Launches to Advance YY003, an Investigational Recombinant Botulinum Toxin Type A in a Ready-to-Use Liquid Formulation

Company aims to deliver the first FDA-approved recombinant botulinum neurotoxin type A (rBoNT/A) Phase II study in moderate-to-severe glabellar lines completed; topline data expected in Q3 2026 Dustin Sjuts, former President of Revance Therapeutics, has been appointed Chief Executive Officer, bringing 20 years of biopharma leadership in commercial strategy and product launches NASHVILLE, Tenn., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Revelyx Bio, Inc., a clinical-stage biopharmaceutical company, today announced its launch following an exclusive licensing agreement with Chongqing Claruvis Pharmaceutical Co., Ltd., for YY003, a ready-to-use liquid formulation of recombinant botulinum toxin type A (rBoNT/A). Under the terms of agreement, Revelyx holds exclusive rights to develop and commercialize YY003 for aesthetic and therapeutic indications globally, excluding mainland China, Hong Kong and Macau. Additionally, the company announced the appointment of Dustin Sjuts as Chief Executive Officer and member of its Board of Directors. “Revelyx is focused on combining YY003’s differentiated science with a clear development path to bring next-generation recombinant innovation to an established, fast-growing market,” said Dustin Sjuts, Chief Executive Officer of Revelyx Bio. “We will advance our lead asset with disciplined execution across clinical development, regulatory strategy and CMC as we prepare to report topline Phase II results and position the program for late-stage development.” From Conventional Fermentation to Precision Genetic Engineering YY003 is an investigational rBoNT/A formulated as a ready-to-use liquid and presented in a prefilled syringe. Produced via recombinant expression in E. coli rather than traditional Clostridium botulinum culture purification, the manufacturing process offers precise control over neurotoxin identity and purity. The resulting protein is structurally identical to naturally derived neurotoxin, offering the potential for high specific activity and enhanced safety profile. Recombinant manufacturing is a proven, highly scalable platform used to produce biologic medicines for over 40 years. YY003 builds on Claruvis Pharmaceutical’s proprietary recombinant platform, which also underpins Retoxin® (YY001). In March 2026, Claruvis secured approval from China’s National Medical Products Administration (NMPA) for Retoxin® to temporarily improve moderate-to-severe glabellar lines in adults - marking the world’s first approved rBoNT/A. Retoxin® is currently commercially available in China, with pivotal Phase III data published in Aesthetic Surgery Journal . Claruvis is also advancing Retoxin® in a Phase III trial in China for adult upper-limb spasticity secondary to stroke. Phase II Study of YY003 in Moderate-to-Severe Glabellar Lines Completed The U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug application for YY003 in September 2024. A randomized, double-blind, vehicle-controlled Phase II study of YY003 in adults with moderate-to-severe glabellar lines has been completed at clinical sites in Australia. Revelyx expects to report topline results in Q3 2026. “Having founded and led BioBAY, I have seen firsthand the quality and scale of innovation emerging from China’s biotechnology ecosystem,” said Xianghong Lin, Founding Partner of NRL Capital and original Founder of BioBay. “NRL incubated Revelyx to bring that innovation to global markets by pairing high-potential clinical programs with robust development, regulatory, CMC and commercial leadership required to advance them. YY003 is a compelling first example of this strategy, and Dustin brings the ideal operating experience and vision to lead it through the next stages of global growth.” Mr. Sjuts brings over 20 years of experience building and scaling public and private life sciences companies. Through his career, he has advanced biologics, specialty pharmaceuticals and medical technologies from clinical development through manufacturing and commercialization, with deep expertise in injectable therapies and neuromodulators. Most recently, Mr. Sjuts served as President of Revance Therapeutics, where he oversaw commercial, clinical, regulatory and technical operations. During his tenure, he led the FDA approvals and U.S. commercial launches of DAXXIFY® (daxibotulinumtoxinA-lanm) for moderate-to-severe glabellar lines and cervical dystonia in adults, as well as the U.S. commercial launch of the RHA® Collection of dermal fillers. Before becoming President, he served as the company’s Chief Commercial Officer. Earlier, Mr. Sjuts led Galderma’s aesthetics business in Greater China from Shanghai and held commercial leadership roles at Allergan. About Revelyx Bio Revelyx Bio, Inc. is a private, clinical-stage biopharmaceutical company developing and advancing differentiated therapies sourced from Asia-Pacific innovators for the United States and other global markets. The company combines selective in-licensing with expertise in clinical development, regulatory strategy, chemistry, manufacturing and controls (CMC), and commercialization. Its lead program, YY003, is an investigational recombinant botulinum toxin type A in a ready-to-use liquid formulation being developed for aesthetic and therapeutic indications. Revelyx holds exclusive rights to develop and commercialize YY003 in all territories outside mainland China, Hong Kong and Macau. Learn more at or connect with us on LinkedIn . About Claruvis Chongqing Claruvis Pharmaceutical Co., Ltd., a subsidiary of MingMed Biotechnology, is a biopharmaceutical company dedicated to developing recombinant botulinum toxin products for aesthetic and therapeutic indications. Claruvis developed Retoxin® (YY001), the world’s first approved recombinant botulinum toxin type A (rBoNT/A), and continues to advance a robust pipeline powered by its proprietary recombinant neurotoxin technology. For more information, visit MingMed Biotechnology at . Trademarks DAXXIFY® is a registered trademark of Revance Therapeutics, Inc. RHA® is a registered trademark of TEOXANE SA. Retoxin® is a registered trademark of Chongqing Claruvis Pharmaceutical Co., Ltd. Media Inquiries info@revelyx.com A photo accompanying this announcement is available here .

引进/卖出临床2期高管变更临床3期上市批准

2026-08-19

·美通社

复锐医疗科技2026年中期经营展现稳健发展韧性

注射填充业务高速增长，亚太市场驱动国际收入稳步上行香港 2026年8月19日 /美通社/ -- 复锐医疗科技有限公司（英文 "Sisram" ；简称 "公司" 或 "复锐医疗科技" ，股票代码：1696.HK，连同其附属公司统称" 集团 "），一家全球化的美丽健康集团，致力于以能量源设备及注射填充产品为核心构建客户导向的美丽健康生态系统，今日公布截至2026年6月30日止六个月（ "报告期" ）之未经审核综合中期业绩。报告期内，公司凭借注射填充业务的加速推进与亚太市场的亮眼表现，有效对冲了北美市场的挑战和宏观不确定性，整体保持稳健增长，展现出强劲的经营韧性与战略定力。财务概览集团实现总收入171.4百万美元，同比增长3.6%，整体经营保持稳健。国际市场 ① （除北美）收入为127.0百万美元，同比增长16.7%。分区域来看，亚太、欧洲、中东及非洲收入分别为78.4百万美元、26.7百万美元和16.8百万美元，同比增幅依次达19.1%、12.1%和20.9%。北美实现收入44.4百万美元，同比下降21.6%，其中，加拿大收入同比增长超20.0%，显现北美地区局部复苏态势。能量源设备业务（除北美）收入为97.1百万美元，同比增长7.2%。注射填充业务收入为22.2百万美元，同比增长54.2%，占总收入的12.9%，成为公司第二增长引擎。毛利率为56.7%，2025年同期为60.0%。毛利率下降主要受区域收入占比变动和产品组合变化的影响。净利润为1.1百万美元，2025年同期为9.0百万美元。净利润率为0.6%，2025年同期为5.4%。该变动主要源于公司在中国注射剂业务的持续投入，叠加北美市场表现承压。针对该情况，公司已主动对北美地区的业务模式、运营执行效率及成本结构开展优化调整。经调整净利润为5.0百万美元，2025年同期为12.0百万美元。经调整净利润率为2.9%，2025年同期为7.2%。主要业务进展能量源设备业务：核心平台韧性凸显，本土化布局加速落地复锐医疗科技持续深耕能量源核心技术、构筑深厚技术壁垒，稳步夯实全球医美设备赛道的领先地位。公司旗舰多功能平台Alma Harmony与Hybrid系列，依托一体化多功能平台优势与成熟落地的临床诊疗体系，多年来保持稳健增长，品牌行业影响力稳步攀升，充分印证了公司能量源设备的长期发展韧性与全球竞争力。与此同时，2026年6月，旗下Soprano Titanium设备成功登陆泰国市场，上市后迅速获得当地头部医美机构的认可与积极反馈，进一步打通区域市场能量源设备与注射填充业务的协同链路，完善品类联动、双向赋能的商业化发展格局。依托全球业务基本盘，公司聚焦亚太增量市场深入本土化运营，迭代适配区域需求的专属设备与定制化治疗方案。2026年7月，公司完成两大核心市场产品投放：面向中国香港推出Titanium Prime联合疗法，同步在中国大陆上市全新能量源设备"黑金牛奶光"，进一步完善亚太地区产品及诊疗服务矩阵，深度契合了消费者从单一肌肤修复转向长效、一体化肌肤综合管理的消费升级趋势。此外，中国本土化生产布局也取得里程碑式进展。2026年6月，北京密云生产基地正式投产，首台国产能量源设备Alma Rejuve顺利下线，标志着公司中国本土化战略迈入实质运营新阶段。该基地全面沿用以色列成熟生产工艺与严格质控体系，既优化了供应链，也确保了产品品质的稳定统一，为公司深耕中国市场、辐射亚太全域业务搭建核心产业支撑。注射填充业务：增长势能持续释放，差异化产品管线稳步推进注射填充业务延续2025年高增态势，作为公司第二增长曲线持续释放增长动能。核心产品达希斐在中国大陆商业化落地成效突出，自2026年1月上市至期末，到诊所端累计出库量突破30,000支，合作覆盖近500家高端医美机构，增长依托终端机构采购渗透率提升及标准化医师培训体系持续落地。公司以标杆医美机构为核心合作载体，配套标准化临床培训、精细化终端运营服务及本土化定制注射方案，持续拉动产品临床应用频次与客户复购水平，夯实高端肉毒赛道市场定位，持续加深渠道渗透力度。明星产品 Profhilo 依托高浓度透明质酸差异化产品特性，获得泰国主流医美机构普遍认可，持续筑牢公司在亚太地区的品牌竞争壁垒。创新无BDDE交联透明质酸填充剂Hallura已于 2025年在以色列实现上市，当前全球商业化进程有序推进。总体而言，公司正加快注射填充产品在核心战略市场的布局，进一步完善全球化注射产品管线，强化多品类协同发展效能。智慧美学：标杆产品获市场验证，全球版图持续延伸 AI赋能生态系统在试点市场取得积极进展，展现出超越行业平均水平的客户粘性与复购表现。公司个性化诊断设备Alma IQ入选《Glamour》杂志"2026年度美容创新"榜单，并荣获"最佳AI护肤应用奖"，充分验证AI诊断与个性化解决方案的商业价值。同时，公司AI护肤系统Universkin by Alma在美国市场保持强劲发展势头，并已拓展至德奥瑞（DACH）和中国香港市场。公司计划于2026年下半年进一步扩大市场覆盖，加快构建贯通智能辅助诊断、能量源治疗、注射填充及个性化护肤的综合美学生态系统。展望未来展望2026年下半年，公司将依托上半年的经营积淀，以营收规模稳步提升为导向，聚焦盈利能力修复与整体运营体系提质增效，持续完善覆盖诊断、治疗、养护的全链路美丽健康生态体系。中国市场，公司将加速达希斐的商业化深度拓展，着力打造标杆诊所，完善本土化注射填充解决方案。同时，公司将同步推动新一代能量源设备放量增长，强化能量源设备与注射填充两大核心业务的深度协同，充分释放客户资源、医学教育与供应链之间的联动效应。在此基础上，公司将有序释放中国生产基地的产能，全面提升本土市场的产品交付与供应保障能力。北美市场，公司将聚焦于业绩企稳与盈利修复。通过推出契合医生与消费者需求的新一代能量源设备及配套临床诊疗方案，同时着力提升运营效率、优化成本架构，公司旨在重塑区域竞争优势，重回可持续增长轨道。全球市场，公司将着力改善商业执行能力，把握可及性产品类别的增长机遇，迭代推出新一代能量源设备及配套临床诊疗方案；深化 Alma IQ 智能诊断系统、Universkin by Alma专业护肤线与能量设备的业务融合，针对不同区域市场消费特征打造定制化诊疗平台与配套服务方案，持续扩大AI赋能肌肤管理解决方案的全球覆盖范围。与此同时，公司将积极寻求契合生态体系的投资、并购与合作机会，丰富全品类产品管线、夯实创新研发能力，为公司中长期可持续高质量发展注入增长动能。管理层评论复锐医疗科技董事长Lior Dayan先生表示："随着求美者对长效化、个性化肌肤健康管理需求的持续攀升，全球医疗美容行业正加速从单一项目治疗，向覆盖肌肤诊断、联合治疗及长期养护的综合解决方案演进。复锐医疗科技凭借在能量源设备领域积累的深厚优势，已逐步构建起涵盖能量源设备、注射填充、AI智能诊断及个性化护肤的全链路美丽健康生态体系，为把握行业中长期发展机遇奠定了坚实基础。展望未来，公司将继续坚持创新驱动与全球化发展，深化核心市场布局，巩固全球竞争优势，为客户、求美者及股东创造长期价值。" 复锐医疗科技首席执行官Eyal Ben David先生表示："2026年上半年，公司国际市场与第二增长曲线业务均取得了积极进展。核心能量源设备平台在国际市场延续良好发展势头，充分彰显全球医美专业机构对公司技术实力及临床价值的高度认可。达希斐在中国大陆的商业化逐步提速，叠加Profhilo与Hallura的差异化产品优势，大幅拓展了公司在高端注射赛道的覆盖深度，巩固了注射填充业务第二增长引擎的战略地位，驱动板块实现强劲增长。与此同时，公司进一步完善研发体系建设，加强资源配置与跨职能协作效率，有力推动重点研发项目及核心产品管线加速落地。展望未来，我们将坚持以能量源设备为业务根基，以注射填充业务为增长引擎，聚焦亚太及北美等核心战略市场，加快核心产品与治疗方案的商业化落地，为客户与求美者提供更全面、更具价值的一体化美丽健康解决方案。" 复锐医疗科技联席首席执行官兼首席财务官李家宏先生表示："2026年上半年，尽管北美市场持续承压，依托国际市场及注射填充业务双向拉动，公司整体营收同比提升3.6%，其中，第二季度收入同比及环比均实现较强增长，充分验证多区域、多品类布局赋予公司的经营韧性。在利润端，受美国市场收入下滑及中国注射填充业务战略性投入影响，盈利水平出现阶段性调整。针对这一短期波动，公司已积极部署改善举措，下半年将持续强化成本管控纪律性，深化成本优化与运营效率提升，全面提升经营质量，盈利能力、现金转化效率及运营效能。面向未来，依托稳健的财务基本面与清晰的战略方向，公司有信心通过内生外延并举，实现更高质量的增长，为股东创造长期可持续价值。" ①国际市场指不包括北美在内的全球其他市场关于复锐医疗科技复锐医疗科技有限公司（股票代码：1696.HK）是一家全球化的美丽健康集团，拥有逾25年能量源设备（EBD）领域的专业经验。公司以技术创新与临床卓越为根基，构建了涵盖能量源设备、注射填充产品、诊断及协同解决方案的生态系统。公司业务遍及全球110多个国家和地区，通过提供屡获殊荣的卓越产品，公司为全球数百万消费者在安全、有效及个性化医美护理领域树立了新标杆。复锐医疗科技为中国领先的医疗健康产业集团复星医药的控股子公司，自2017年9月起在香港联合交易所主板上市。更多信息，请访问： www.sisram-medical.com 。前瞻性声明本新闻稿中传达的信息包含某些具有或可能具有前瞻性的陈述。这些陈述通常包含诸如"将"、"期望"、"相信"、"计划"和"预期"等词语以及类似含义的词语。就其性质而言，前瞻性陈述涉及风险和不确定性，因为它们与事件相关并取决于未来将发生的情况。可能存在目前被认为不重要或本公司未意识到的其他重大风险。该等前瞻性陈述并非对未来业绩的保证。在此等不确定性的背景下，读者不应依赖该等前瞻性陈述。前瞻性陈述可能更新或根据未来的事件或发展进行相应修改，对此本公司不承担任何责任。投资者咨询，请联系： IR@sisram-medical.com

100 项与 Daxibotulinumtoixn A-LANM 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10921	-	M03AX01	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肌张力障碍	中国	上海复星医药产业发展有限公司	2024-11-22
颈肌张力障碍	美国	Revance Therapeutics, Inc.	2023-08-11
眉间纹	美国	Revance Therapeutics, Inc.	2022-09-07

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
斜颈	申请上市	美国	Revance Therapeutics, Inc.	2022-10-20
孤立性颈部肌张力障碍	临床3期	美国	Revance Therapeutics, Inc.	2018-06-20
孤立性颈部肌张力障碍	临床3期	奥地利	Revance Therapeutics, Inc.	2018-06-20
孤立性颈部肌张力障碍	临床3期	加拿大	Revance Therapeutics, Inc.	2018-06-20
孤立性颈部肌张力障碍	临床3期	捷克	Revance Therapeutics, Inc.	2018-06-20
孤立性颈部肌张力障碍	临床3期	法国	Revance Therapeutics, Inc.	2018-06-20
孤立性颈部肌张力障碍	临床3期	德国	Revance Therapeutics, Inc.	2018-06-20
孤立性颈部肌张力障碍	临床3期	波兰	Revance Therapeutics, Inc.	2018-06-20
孤立性颈部肌张力障碍	临床3期	西班牙	Revance Therapeutics, Inc.	2018-06-20
孤立性颈部肌张力障碍	临床3期	英国	Revance Therapeutics, Inc.	2018-06-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05158166 (CTgov)	临床1/2期	痉挛性发声困难	22	DaxibotulinumtoxinA	製築餘觸獵醖餘膚鹹蓋(艱築蓋糧鏇醖鹹獵願淵) = 觸夢膚廠糧鬱願夢積鬱選艱網製鏇顧淵艱鏇網 (衊膚選壓鹹獵獵醖壓窪, 8.18) 更多	-	2026-03-27
CTR20202553 (Pubmed)	-	面部皱纹	307	Daxxify	艱網遞蓋遞築艱繭衊獵(壓蓋壓顧壓膚鑰築襯壓) = 壓構選範齋構鹽網艱範齋廠選選憲顧築鬱醖範 (網觸艱鹽簾壓鏇鬱獵積 ) 更多	积极	2024-12-01
				安慰剂	艱網遞蓋遞築艱繭衊獵(壓蓋壓顧壓膚鑰築襯壓) = 網餘遞遞鏇簾範獵簾製齋廠選選憲顧築鬱醖範 (網觸艱鹽簾壓鏇鬱獵積 )
ASPEN-1 (MDS2024)	临床3期	颈肌张力障碍	321	DaxibotulinumtoxinA	醖醖膚簾壓獵餘艱糧構(淵鑰範觸積築遞醖膚鹽) = 醖鏇襯窪簾願膚醖顧鏇廠餘餘選艱選艱淵鑰遞 (憲壓蓋蓋顧範衊壓壓觸 ) 更多	积极	2024-09-27
AAN2024	N/A	颈肌张力障碍	-	DaxibotulinumtoxinA	鹹觸鑰餘築夢構衊餘顧(築鹹鹹製窪蓋顧顧鑰壓) = 範壓廠鹽積餘襯製願願夢廠醖獵積襯艱網顧齋 (構鑰繭範鹽淵齋鹹積廠 ) 更多	-	2024-04-09
NCT02973269 (CTgov)	临床2期	足底筋膜炎	7	daxibotulinumtoxin type A (DAXI 240 U)	鏇齋膚築構鏇鬱艱鬱糧(鑰選襯淵膚鏇繭製蓋簾) = 觸網顧窪鑰壓壓鏇鏇繭鹽觸廠膚鹽獵齋積鏇願 (壓蓋壓製構鑰構範鑰襯, 11.0) 更多	-	2024-04-03
				Placebo (Placebo)	鏇齋膚築構鏇鬱艱鬱糧(鑰選襯淵膚鏇繭製蓋簾) = 艱顧齋齋鹹窪鹹餘範夢鹽觸廠膚鹽獵齋積鏇願 (壓蓋壓製構鑰構範鑰襯, 12.1) 更多
NCT03608397 \| EUCTR2018-000446-19-AT (ASPEN-1, Pubmed \| Neurology) 人工标引	临床3期	颈肌张力障碍	301	DAXI125U	選獵築夢窪網膚築淵艱(簾艱齋艱製網衊窪艱簾) = 衊窪艱襯窪艱範網鹹襯鑰簾壓簾鬱網繭網鬱範 (廠範積餘壓壓範顧鏇餘, 1.30) 更多	积极	2024-01-31
				DAXI250U	選獵築夢窪網膚築淵艱(簾艱齋艱製網衊窪艱簾) = 願範築願鬱顧鹽積築獵鑰簾壓簾鬱網繭網鬱範 (廠範積餘壓壓範顧鏇餘, 1.25) 更多
NCT03825315 (CTgov)	临床2期	足底筋膜炎	155	DAXI 80 U (DAXI 80 U)	網鹹衊製顧鹽艱鏇網願(鹹鹽遞鹽衊廠夢獵鏇鏇) = 憲願衊夢憲範鹹繭窪鹹廠鹹齋獵廠窪淵襯淵構 (鬱願艱餘選積觸顧觸積, 0.329) 更多	-	2023-09-21
				DAXI 120 U (DAXI 120 U)	網鹹衊製顧鹽艱鏇網願(鹹鹽遞鹽衊廠夢獵鏇鏇) = 範願襯願鏇積衊選製獵廠鹹齋獵廠窪淵襯淵構 (鬱願艱餘選積觸顧觸積, 0.298) 更多
NCT03821402 (JUNIPER, CTgov)	临床2期	脑卒中 \| 上下肢痉挛 \| 创伤性脑损伤 ... 更多	83	DAXI (DAXI 250 U)	選積簾鬱廠鏇鑰願繭製(繭齋鏇鹽範顧顧遞積觸) = 獵廠願鬱遞膚衊膚齋襯廠蓋淵築網醖鏇築遞簾 (鏇齋膚憲網窪鬱構蓋廠, 0.25) 更多	-	2023-09-21
				DAXI (DAXI 375 U)	選積簾鬱廠鏇鑰願繭製(繭齋鏇鹽範顧顧遞積觸) = 製餘構餘獵構構膚壓淵廠蓋淵築網醖鏇築遞簾 (鏇齋膚憲網窪鬱構蓋廠, 0.26) 更多
GL-2 (FDA) 人工标引	N/A	眉间纹	609	DAXXIFY (STUDY GL-1)	襯顧齋壓廠齋淵簾廠鏇(鏇獵願繭窪製糧膚窪襯) = 壓製範構蓋糧願鏇鑰鬱壓繭壓鑰齋憲衊築構簾 (窪顧選鏇顧衊糧構壓觸 ) 更多	积极	2023-08-11
				Placebo (STUDY GL-1)	襯顧齋壓廠齋淵簾廠鏇(鏇獵願繭窪製糧膚窪襯) = 鹽蓋齋蓋廠顧夢積鏇壓壓繭壓鑰齋憲衊築構簾 (窪顧選鏇顧衊糧構壓觸 ) 更多
NCT03608397 (FDA) 人工标引	临床3期	颈肌张力障碍	301	Placebo	憲醖艱鬱艱簾鬱窪窪網(簾艱繭襯艱獵夢繭淵鹹) = 醖製廠淵簾獵簾醖蓋窪繭鹹襯構鬱襯醖製鏇齋 (憲願鹽製蓋廠齋蓋製艱 )	积极	2023-08-11
				DAXI 125 U	憲醖艱鬱艱簾鬱窪窪網(簾艱繭襯艱獵夢繭淵鹹) = 衊簾衊鏇範餘醖醖餘築繭鹹襯構鬱襯醖製鏇齋 (憲願鹽製蓋廠齋蓋製艱 )